Published in Medicine and Law Weekly, March 11th, 2005
PDI's metabolomics-based technology enables the discovery of metabolites that differ between healthy controls and people with Alzheimer disease and bipolar disorder. Such diagnostic metabolites can be used for the early detection of disease, as well as to optimize and measure response to treatment regimes.
"The scientific value of genetic samples is a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly